A Study of TAK-071 in People With Parkinson Disease

NCT ID: NCT04334317

Last Updated: 2024-05-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 64 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-10-21
• Study Completion Date: 2023-02-27

Brief Summary

It is hoped that TAK-071 will help people with Parkinson's disease to walk with better balance. The main aim of the study is to check if there is a difference in how participants walk after treatment with TAK-071. Another aim is to see if it improves how participants think and remember.

At the first visit, the study doctor will check who can take part. Participants who can take part will be picked for 1 of 2 groups by chance.

Both groups will have 2 treatments but in a different order. The treatments are TAK-071 tablets or placebo. In this study, a placebo will look like the TAK-071 but will not have any medicine in it.

One group will take TAK-071 for 6 weeks, have at least a 3-week break, then take a placebo for 6 weeks. The other group will take a placebo for 6 weeks, have at least a 3-week break, then take TAK-071 for 6 weeks. The participants will not know the order of their 2 treatments, nor will their study doctors. This is to help make sure the results are more reliable.

The participants will visit the clinic at the beginning and end of each treatment for a check-up. 14 days after the 2nd treatment, clinic staff will telephone the participants for a final check-up.

Detailed Description

The drug being tested in this study is TAK-071. TAK-071 is being tested to treat people with PD who have cognitive impairment and are at risk for falls and who are not concurrently taking acetylcholinesterase inhibitors. The study will look at the efficacy and safety of TAK-071 in participants with PD who take TAK-071 versus placebo.

The study will also evaluate the PK of TAK-071 in healthy participants (sentinel cohort) older than 55 years.

The study will enroll approximately 74 participants. An initial sentinel cohort of 10 healthy participants will be included to estimate age effects. Participants aged 56 to 75 years will be randomly assigned in 3:1 ratio to one of the two treatments:

• Sentinel Cohort: TAK-071 7.5 mg
• Sentinel Cohort: Placebo

Enrolment for participants aged 40 to ≤ 85 years in the main study will start simultaneously with sentinel cohort. Based on PK, safety, and physiologically based PK modelling data from sentinel cohort, dosing will be decided for the remaining participants. Participants with maximum age of 66 to 85 years, inclusive, will be enrolled at a dose of 5 mg, and the dose for subjects aged 40 to 65 years, inclusive, will be 7.5 mg. All participants will be asked to take one tablet at the same time each day throughout the study.

The remaining participants aged 40 years to <=85 years will be randomly assigned in 1:1 ratio to one of two treatment sequences in crossover design:

• TAK-071 + Placebo
• Placebo + TAK-071

The study will be conducted in the United States. The minimum time to participate in this study is approximately 15 weeks. Participants will make multiple visits to the clinic and will have home assessments during the third Week of each 6-week treatment period, and will be contacted by telephone at 14 days after completion of the last period for a follow-up assessment.

Conditions

Parkinson Disease; Healthy Participants

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo + TAK-071 (PD Participants)

TAK-071 placebo-matching tablets, orally, once daily for up to first 6 weeks in Period 1, followed by ≥3 weeks washout period, followed by TAK-071 tablets, orally, once daily for up to next 6 weeks in Period 2.

Group Type: EXPERIMENTAL

TAK-071

Intervention Type: DRUG

TAK-071 tablet.

Placebo

Intervention Type: DRUG

TAK-071 placebo-matching tablet.

TAK-071 + Placebo (PD Participants)

TAK-071 tablets, orally, once daily for up to first 6 weeks in Period 1, followed by ≥3 weeks washout period, followed by TAK-071 placebo-matching tablets, orally, once daily for up to next 6 weeks in Period 2.

Group Type: EXPERIMENTAL

TAK-071

Intervention Type: DRUG

TAK-071 tablet.

Placebo

Intervention Type: DRUG

TAK-071 placebo-matching tablet.

Sentinel Cohort: Placebo (Healthy Participants)

A single dose of TAK-071 placebo-matching mg, tablet, orally, on Day 1.

Group Type: EXPERIMENTAL

Placebo

Intervention Type: DRUG

TAK-071 placebo-matching tablet.

Sentinel Cohort: TAK-071 7.5 mg (Healthy Participants)

A single dose of TAK-071 ≤ 7.5 milligrams (mg), tablet, orally, on Day 1.

Group Type: EXPERIMENTAL

TAK-071

Intervention Type: DRUG

TAK-071 tablet.

Interventions

TAK-071

TAK-071 tablet.

Intervention Type: DRUG

Placebo

TAK-071 placebo-matching tablet.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Is an outpatient of any sex aged between 40 and ≤ 85 years, inclusive, at the time of consent.

2. Has a diagnosis of PD according to Movement Disorders Society (MDS) clinical diagnostic criteria for PD. Participants with DLB (i.e., dementia diagnosed before onset of motor symptoms or up to 1 year after onset of motor symptoms) are also eligible, consistent with MDS clinical diagnostic criteria for PD.

3. Has Hoehn and Yahr stage ≥2 and <4 at the screening visit.

4. Has elevated risk for falls as indicated by at least 1 fall in the last 12 months before the screening visit based on the Fall History Assessment where in the opinion of the investigator the falls were a consequence of PD and are at continued elevated risk of falls per investigator judgment. Investigator judgment on fall risk may be informed by information such as, but not limited to, history, physical examination and/or a score ≥2 on item 3.10 on Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III.

5. Has evidence of cognitive impairment as indicated by a Montreal Cognitive Assessment (MoCA) score between 11 and 26, inclusive and additionally can complete the cognitive assessments at screening (as specified in the study manual).

6. Can walk without aid for 2 minutes while doing serial 3 subtraction (with site staff ensuring participant safety in case of falls). Participants who require aids for walking can be included as long as they can complete the walk test without aid.

Inclusion For Healthy Participants:

1. The participant is a healthy individual of either sex aged between 56 and 75 years, inclusive (for initial set of participant in the sentinel cohort) at the time of consent. Older participants may be enrolled after analysis of data from participants aged 56 to 75 years, inclusive.

Exclusion Criteria

1. Has orthostatic hypotension at screening, as defined as a decline in systolic blood pressure greater than 20 mm Hg or a decrease of 10 mm Hg in diastolic blood pressure on standing measured within 1 minute after being supine for at least 5 minutes.

2. Has dyskinesia of sufficient severity to interfere with digital gait assessments during visits (as defined by Movement Disorders Society - Unified Parkinson's Disease Rating Scale [MDS-UPDRS] section 4.1 "Time spent with dyskinesias" and/or section 4.2 "Functional Impact of Dyskinesias" scores greater than [>] 2), or in the opinion of the investigator the participant's dyskinesia is likely to interfere with the digital gait assessments.

3. Has significant risk factors for seizures (a history of seizures as an adult, a history of brain injury, or other risk factors deemed relevant by the investigator).

4. Is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property, or the participant has attempted suicide within the past year before screening. Participants who have positive answers on item number 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) (based on the past year) before randomization are excluded.

5. Is unwilling or unable to discontinue taking cholinesterase inhibitors and/or moderate or strong cytochrome P-450 3A4 inhibitors or inducers at least 30 days before randomization.

Exclusion For Healthy Participants:

1. Participants has body mass index (BMI) less than 18 or greater than 40.

2. Has significant risk factors for seizures (a history of seizures as an adult, a history of brain injury, or other risk factors deemed relevant by the investigator).

3. The participant is unwilling or unable to discontinue taking cholinesterase inhibitors and/or moderate or strong CYP 3A4 inhibitors or inducers at least 30 days before randomization.

4. The participant is taking warfarin.

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Michael J. Fox Foundation for Parkinson's Research

OTHER

Sponsor Role: collaborator

Takeda

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Study Director

Role: STUDY_DIRECTOR

Takeda

Locations

Collaborative Neuroscience Network, LLC

Garden Grove, California, United States

University of California Irvine Medical Center

Irvine, California, United States

Cedars Sinai Medical Center

Los Angeles, California, United States

Rocky Mountain Movement Disorders Center

Englewood, Colorado, United States

PPD Phase 1 Clinic

Orlando, Florida, United States

Infinity Clinical Research, LLC

Sunrise, Florida, United States

USF Medical Clinic

Tampa, Florida, United States

Augusta University

Augusta, Georgia, United States

Feinberg School of Medicine Northwestern University

Chicago, Illinois, United States

Indiana University Health Neuroscience Center

Indianapolis, Indiana, United States

Quest Research Institute - Hunt - PPDS

Farmington Hills, Michigan, United States

Park Nicollet Health Services

Golden Valley, Minnesota, United States

University of Rochester Medicine - Movement Disorders Unit

Rochester, New York, United States

Neurology Diagnostics, Inc. - ERG - PPDS

Dayton, Ohio, United States

University of Philadelphia

Philadelphia, Pennsylvania, United States

Medical University of South Carolina - PPDS

Charleston, South Carolina, United States

Baylor College of Medicine

Houston, Texas, United States

Central Texas Neurology

Round Rock, Texas, United States

Meridian Clinical Research

Norfolk, Virginia, United States

Evergreen Hospital Medical Center

Kirkland, Washington, United States

Inland Northwest Research

Spokane, Washington, United States

Countries

United States

References

Shanbhag NM, Padmanabhan JL, Zhang Z, Harel BT, Jia H, Kangarloo T, Yin W, Dowling AV, Laurenza A, Khudyakov P, Galinsky K, Latzman RD, Simuni T, Weintraub D, Horak FB, Lustig C, Maruff P, Simen AA. An Acetylcholine M1 Receptor-Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment: A Phase 2 Randomized Clinical Trial. JAMA Neurol. 2025 Feb 1;82(2):152-159. doi: 10.1001/jamaneurol.2024.4519.

Reference Type: DERIVED

PMID: 39761063 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

https://clinicaltrials.takeda.com/study-detail/5f6b603d4db2bf003ab4a39d

Related Info

Other Identifiers

U1111-1247-0357

Identifier Type: OTHER

Identifier Source: secondary_id

TAK-071-2002

Identifier Type: -

Identifier Source: org_study_id